# Immunotherapy in Lymphoma

> **NCT06796517** · — · RECRUITING · sponsor: **Sung-Soo Park** · enrollment: 72 (estimated)

## Conditions studied

- Relapsed/refractory High Grade B Cell Lymphoma
- High Grade B-cell Lymphoma
- Diffuse Large B Cell Lymphoma Relapsed
- Primary Mediastinal Large B-Cell Lymphoma
- Burkitt Lymphoma

## Interventions

- **DRUG:** CAR-T Therapy
- **DRUG:** Bispecific antibody
- **DRUG:** Antibody-Drug Conjugate
- **DRUG:** Monoclonal antibody
- **DRUG:** Proteasome Inhibitor
- **DRUG:** IMiD treatment

## Key facts

- **NCT ID:** NCT06796517
- **Lead sponsor:** Sung-Soo Park
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-26
- **Primary completion:** 2025-12
- **Final completion:** 2025-12-31
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2025-01-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06796517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06796517, "Immunotherapy in Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06796517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*